# Bouts of vomiting, nausea and abdominal pain: The little-known syndrome stalking daily … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/bouts-of-vomiting-nausea-and-abdominal-pain-the-little-known-syndrome-stalking-daily/ > **Published:** 2026-06-16T10:41:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:23:05-04:00 > **Clinical Summary:** Cannabinoid hyperemesis syndrome diagnosis, recognition in daily cannabis users, and evidence-based clinical management for primary care. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyTHCMental HealthNeurologyDosingPain Why This Matters [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS) is an underrecognized condition that clinicians must screen for in patients presenting with recurrent nausea, vomiting, and abdominal pain, particularly those using cannabis daily. Early diagnosis of CHS prevents unnecessary diagnostic workups and procedures while enabling appropriate counseling about cannabis cessation as the definitive treatment. As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) increases access and potency, clinicians need awareness of this syndrome to identify it promptly and educate patients about this potential serious adverse effect. Clinical Summary [Cannabinoid Hyperemesis Syndrome](https://cedclinic.com/spontaneous-pneumomediastinum-cannabinoid-hyperemesis-case-report/) (CHS) is an underrecognized condition occurring in chronic daily cannabis users characterized by cyclical episodes of severe nausea, vomiting, and abdominal pain that paradoxically improve with hot bathing. This Spanish emergency medicine study adds to growing clinical evidence that CHS represents a genuine medical entity distinct from other causes of recurrent emesis, with prevalence likely underestimated due to physician unfamiliarity and patients’ reluctance to disclose [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). The syndrome appears dose-dependent and related to cumulative THC exposure rather than product contamination, suggesting a direct pharmacological effect in susceptible individuals. Clinicians evaluating patients with unexplained recurrent vomiting should specifically inquire about daily [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and consider CHS in the differential diagnosis, as recognition of this condition can spare patients extensive unnecessary investigations and inappropriate treatments. The practical takeaway is that all physicians, particularly those in emergency and primary care settings, should maintain a high index of suspicion for CHS in frequent cannabis users presenting with refractory nausea and vomiting, and counsel at-risk patients about this potential adverse effect. Dr. Caplan’s Take “Cannabinoid hyperemesis syndrome is real and we’re seeing it more often in our clinics as use patterns shift toward daily consumption, but the underlying mechanism still isn’t fully understood, so while we take these symptoms seriously and counsel patients about stopping use as first-line intervention, we need more prospective research to clarify who’s at highest risk and what dose or cannabinoid profile matters most.” Clinical Perspective 💊 [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS) remains underrecognized in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) despite growing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), particularly among daily users who may not initially connect their symptoms to their consumption pattern. Healthcare providers evaluating patients with recurrent nausea, vomiting, and abdominal pain should consider cannabis use frequency and duration as part of the differential diagnosis, noting that symptoms may paradoxically improve with hot showers—a distinctive clinical feature that can aid identification. The syndrome’s pathophysiology is not fully understood, and individual susceptibility appears variable, meaning some heavy users never develop CHS while others experience severe symptoms, complicating risk stratification. Given the global trend toward [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and increased potency of available products, clinicians should routinely ask about cannabis use patterns in patients presenting with cyclic gastrointestinal complaints, and should educate patients that cessation is the only definitive treatment, as symptom management without 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Bouts%20of%20vomiting%2C%20nausea%20and%20abdominal%20pain%3A%20The%20little-known%20syndrome%20stalking%20daily%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59316)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59316)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Bouts%20of%20vomiting%2C%20nausea%20and%20abdominal%20pain%3A%20The%20little-known%20syndrome%20stalking%20daily%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59316)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://english.elpais.com/health/2026-06-16/bouts-of-vomiting-nausea-and-abdominal-pain-the-little-known-syndrome-stalking-daily-cannabis-users.html](https://english.elpais.com/health/2026-06-16/bouts-of-vomiting-nausea-and-abdominal-pain-the-little-known-syndrome-stalking-daily-cannabis-users.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).